Elekta AB ser. B (EKTAb)

Currency in SEK
53.70
+0.35(+0.66%)
Closed·
Unusual trading volume
High dividend Yield
EKTAb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
51.6554.90
52 wk Range
41.8666.70
Key Statistics
Prev. Close
53.35
Open
52
Day's Range
51.65-54.9
52 wk Range
41.86-66.7
Volume
5.83M
Average Volume (3m)
1.41M
1-Year Change
6.3366%
Book Value / Share
18.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EKTAb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
60.37
Upside
+12.41%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Elekta AB ser. B News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
3 Hold
7 Sell
Ratings:
15 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 60.37
(+12.41% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Sell44.50-17.13%46.00MaintainMay 29, 2026
Citi
Sell45.00-16.20%39.00MaintainMay 22, 2026
Deutsche Bank
Hold60.00+11.73%49.00MaintainMar 13, 2026
Goldman Sachs
Sell60.00+11.73%54.00MaintainDec 02, 2025
UBS
Sell39.00-27.37%34.00MaintainDec 01, 2025

Earnings

Latest Release
May 28, 2026
EPS / Forecast
0.57 / 1.40
Revenue / Forecast
4.76B / 5.01B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -1.36%
Dividend Yield
4.50%
Industry Median 1.84%
Annualized payout
2.40
Paid unevenly
5-Years Growth
+1.76%
Growth Streak

EKTAb Income Statement

Compare EKTAb to Peers and Sector

Metrics to compare
EKTAb
Peers
Sector
Relationship
P/E Ratio
−39.5x20.4x−0.5x
PEG Ratio
0.120.280.00
Price/Book
2.9x1.9x2.6x
Price / LTM Sales
1.2x1.9x3.1x
Upside (Analyst Target)
11.7%57.6%50.7%
Fair Value Upside
Unlock27.9%7.6%Unlock

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Elekta Xoft Axxent and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care support services; Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning that offers in-person and digital training courses on radiotherapy; Elekta Care Community, a self-help center; Elekta Partner Community, an online self-service portal; and Elekta Intellimax for predictive maintenance. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Employees
4353
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
116.73M30.55%6.23B
Other Institutional Investors
153.66M40.22%8.20B
Public Companies & Retail Investors
111.69M29.23%5.96B
Total
382.08M100.00%20.38B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Fourth Swedish National Pension Fund (AP4)9.15%34,964,9101,877,616
T. Rowe Price Group, Inc.5.10%19,490,8521,046,659

People Also Watch

16.13
PUIGb
+1.19%
29.1
ELUXb
+2.47%
26.360
UTDI
+1.46%
242.9
SKFb
-0.98%
23.34
EDEN
-0.09%

FAQ

What Is the Elekta B (EKTAb) Stock Price Today?

The Elekta B stock price today is 53.70 SEK.

What Stock Exchange Does Elekta B Trade On?

Elekta B is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Elekta B?

The stock symbol for Elekta B is "EKTAb."

Does Elekta B Pay Dividends? What’s The Current Dividend Yield?

The Elekta B dividend yield is 4.47%.

What Is the Elekta B Market Cap?

As of today, Elekta B market cap is 20.52B SEK.

What Is Elekta B's Earnings Per Share (TTM)?

The Elekta B EPS (TTM) is -1.36.

When Is the Next Elekta B Earnings Date?

Elekta B will release its next earnings report on Aug 27, 2026.

From a Technical Analysis Perspective, Is EKTAb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Elekta B Stock Split?

Elekta B has split 2 times.

How Many Employees Does Elekta B Have?

Elekta B has 4353 employees.

What is the current trading status of Elekta B (EKTAb)?

As of May 30, 2026, Elekta B (EKTAb) is trading at a price of 53.70 SEK, with a previous close of 53.35 SEK. The stock has fluctuated within a day range of 51.65 SEK to 54.90 SEK, while its 52-week range spans from 41.86 SEK to 66.70 SEK.

What Is Elekta B (EKTAb) Price Target According to Analysts?

The average 12-month price target for Elekta B is 60.37 SEK, with a high estimate of 100 SEK and a low estimate of 39 SEK. 5 analysts recommend buying the stock, while 7 suggest selling, leading to an overall rating of Neutral. The stock has an +12.41% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.